SNWV

#4342
SANUWAVE Health, Inc. - Common Stock
4.6 8 USD
0.00%
Market Price
Settore: Salute
Base: USD
Valuta di Profitto: USD
Intervallo Giornaliero
4.68
4.68
Intervallo Annuale
4.50
25.62
Variazione giornaliera
+0.43%
Variazione Mensile
-25.60%
Variazione di 6 mesi
-80.50%
Variazione Annuale
-80.64%
Chiusura Precedente
4.6 6
Open
4.6 8
Minimo
4.6 8
Massimo
4.6 8
Volume
7
Apri il grafico completo

Financials

Panoramica Estratto Conto Statistiche Documents

2026

Current report, Q3 FY2026
SANUWAVE Health, Inc. current report, Q3 FY2026
8-K
Current report, Q3 FY2026
SANUWAVE Health, Inc. current report, Q3 FY2026
8-K
Quarterly report, Q2 FY2026
SANUWAVE Health, Inc. quarterly report, Q2 FY2026
10-Q
Current report, Q2 FY2026
SANUWAVE Health, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
SANUWAVE Health, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
SANUWAVE Health, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
SANUWAVE Health, Inc. current report, Q2 FY2026
8-K
Quarterly report, Q1 FY2026
SANUWAVE Health, Inc. quarterly report, Q1 FY2026
10-Q
Current report, Q1 FY2026
SANUWAVE Health, Inc. current report, Q1 FY2026
8-K
Current report, Q1 FY2026
SANUWAVE Health, Inc. current report, Q1 FY2026
8-K

SANUWAVE Health, Inc. current report, Q2 FY2022

Full document

Business Context and Reporting Period

This Form 8-K Current Report was filed by SANUWAVE Health, Inc. on April 15, 2022, covering events occurring on April 10, 2022. The filing primarily addresses significant changes to the Company's Board of Directors.

Financial Metrics

The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance changes and does not contain financial performance data.

Material Changes

  • Resignation: Mr. John Nemelka resigned as a member of the Board of Directors effective immediately on April 10, 2022. The resignation was not the result of any disagreement with the Company.
  • Appointments: Messrs. Jeffrey Blizard, Ian Miller, and Jim Tyler were appointed to the Board effective immediately on April 10, 2022.
  • Committee Assignments:
    • Jeffrey Blizard: Chairman of the Compensation Committee; member of the Audit Committee and Nominating and Corporate Governance Committee.
    • Ian Miller: Chairman of the Audit Committee (effective upon filing of the 2021 10-K); member of the Nominating and Corporate Governance Committee.
    • Jim Tyler: Chairman of the Nominating and Corporate Governance Committee; member of the Compensation Committee.
    • Mr. Stolarski: Member of the Compensation Committee and Acting Chairman of the Audit Committee until the 2021 10-K is filed.
  • Compensation: The new directors will receive the Company's standard non-employee director cash and equity compensation.

Guidance, Outlook, and Risks

The filing does not contain financial guidance, outlook, or management commentary regarding business operations. No risks, contingencies, or unusual items were disclosed in this specific report. The Company issued a press release on April 12, 2022, regarding these appointments, which is furnished as an exhibit but not deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934.

Key Facts for Investor Verification

  • Verify the effective dates of the new directors' terms, which expire at the next annual meeting.
  • Confirm the specific composition of the Audit Committee once the 2021 10-K is filed, as Mr. Miller's role as Chairman is contingent on that filing.
  • Review the Company's standard non-employee director compensation package to understand the equity implications of the new appointments.
  • Check for any subsequent filings regarding the 2021 10-K to confirm the transition of Audit Committee leadership.